U.S. Markets closed
  • S&P 500

    4,145.19
    -6.75 (-0.16%)
     
  • Dow 30

    32,803.47
    +76.67 (+0.23%)
     
  • Nasdaq

    12,657.55
    -63.04 (-0.50%)
     
  • Russell 2000

    1,921.82
    +15.36 (+0.81%)
     
  • Crude Oil

    88.53
    -0.01 (-0.01%)
     
  • Gold

    1,792.40
    -14.50 (-0.80%)
     
  • Silver

    19.86
    -0.26 (-1.30%)
     
  • EUR/USD

    1.0187
    -0.0063 (-0.6112%)
     
  • 10-Yr Bond

    2.8400
    +0.1640 (+6.13%)
     
  • Vix

    21.15
    -0.29 (-1.35%)
     
  • GBP/USD

    1.2071
    -0.0088 (-0.7206%)
     
  • USD/JPY

    134.9700
    +1.9540 (+1.4690%)
     
  • BTC-USD

    23,121.12
    -93.17 (-0.40%)
     
  • CMC Crypto 200

    533.20
    -2.02 (-0.38%)
     
  • FTSE 100

    7,439.74
    -8.32 (-0.11%)
     
  • Nikkei 225

    28,175.87
    +243.67 (+0.87%)
     

DENTSPLY SIRONA (XRAY) Reports Weak Q1 Preliminary Results

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

DENTSPLY SIRONA Inc. XRAY reported preliminary first-quarter 2022 adjusted earnings per share (EPS) of 52 cents. The Zacks Consensus Estimate for earnings is pegged at 50 cents. Going by this preliminary announcement, the bottom line declined 27.5% from the prior-year quarter.

Per the same announcement, GAAP EPS in the quarter was 30 cents, down 43.8% from the year-ago quarter.

The stock has lost 11.8% during the first-quarter period, compared with the industry’s decline of 2.2%.

Revenues

Per the preliminary results, revenues in the quarter under review amounted to $965 billion, down 6.1% from the year-ago quarter. The consensus mark for revenues is pegged at $965.5 million.

Business Details

Following are the preliminary segment results for the quarter under review:

Consumables

Consumable revenues fell 7.1% year over year and 2.7% on an organic basis in the first quarter to $400 million. Per management, the fall in organic sales was due to lower sales in the United States, the impact of COVID-19 variants on sales volumes in some markets, supply chain challenges and a tough comparison in the prior-year quarter on account of the COVID-19 rebound. However, increased pricing and demand for Endodontic Consumables partially offset the downside.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Technologies & Equipment

Technologies & Equipment revenues were down 5.4% year over year to $565 million in the reported quarter. On an organic basis, net sales fell 0.5%. Supply chain constraints and lower sales in the United States were responsible for the decline in organic sales. However, sustained growth in dentist-directed clear aligners and Implants partially offset the downside.

Revenues by Geography

Per the preliminary announcement, in the United States, revenues fell 13.7% to $299 million. Rest of World revenues decreased 4.6% year over year to $250 million. European revenues declined 0.6% year over year to $416 million.

Margin Analysis

Per the preliminary results, gross profit in the reported quarter amounted to $515 million, down 11.1% on a year-over-year basis. Gross margin was 53.4%, contracting 300 basis points (bps).

Selling, general and administrative expenses were $374 million, down 2.1% from the year-ago quarter. Research and development expenses amounted to $45 million, up 12.5% from the prior-year quarter.

Operating profit was $93 million, down 39.6% from the year-ago quarter. Operating margin was 9.6%, contracting 530 bps on a year-over-year basis.

Financial Condition

Per the preliminary announcement, DENTSPLY SIRONA exited the first quarter of 2022 with cash and cash equivalents of $374 million, up from $339 million sequentially.

According to the same announcement, net cash provided by operating activities at the end of the first quarter was $93 million compared with $49 million in the year-ago period.

2022 Guidance Revised

Per the preliminary announcement, the company projects 2022 revenues within $4.1-$4.2 billion. The Zacks Consensus Estimate for the same is pegged at $4.23 billion. The outlook includes organic sales growth of 2-3%.

The company expects an adjusted EPS of $2.35-$2.55. The Zacks Consensus Estimate for the same stands at $2.60.

Adjusted operating margin is projected to exceed 17% in 2022.

Our Take

Per the preliminary announcement, DENTSPLY SIRONA saw a deterioration in both earnings and revenues. Its core Technology & Equipment and Consumables units witnessed a year-over-year decline in the quarter. Contraction in both gross and operating margins is another headwind.

Nonetheless, the launch of a cloud-based solution and clear aligner solutions, along with meaningful partnership, deserve mention.

Zacks Rank and Key Picks

Currently, DENTSPLY SIRONA has a Zacks Rank #4 (Sell).

Some better-ranked stocks in the broader medical space that have announced quarterly results are Omnicell, Inc. OMCL, UnitedHealth Group Incorporated UNH and Alkermes plc ALKS.

Omnicell, carrying a Zacks Rank #2 (Buy), reported first-quarter 2022 adjusted EPS of 83 cents, which beat the Zacks Consensus Estimate by 16.9%. Revenues of $318.8 million outpaced the consensus mark by 0.7%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Omnicell has an estimated long-term growth rate of 16%. OMCL's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 13.4%.

UnitedHealth, carrying a Zacks Rank #2, reported first-quarter 2022 adjusted EPS of $5.49, which beat the Zacks Consensus Estimate by 1.7%. Revenues of $80.1 billion outpaced the consensus mark by 1.9%.

UnitedHealth has an estimated long-term growth rate of 14.8%. UNH's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.7%.

Alkermes reported first-quarter 2022 adjusted EPS of 12 cents, which beat the Zacks Consensus Estimate of a penny. First-quarter revenues of $278.6 million outpaced the Zacks Consensus Estimate by 6.2%. It currently sports a Zacks Rank #1.

Alkermes has an estimated long-term growth rate of 25.1%. ALKS' earnings surpassed estimates in each of the trailing four quarters, the average surprise being 350.5%.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report

Alkermes plc (ALKS) : Free Stock Analysis Report

Omnicell, Inc. (OMCL) : Free Stock Analysis Report

DENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research